Kornitzer Capital Management’s Maravai LifeSciences MRVI Stock Holding History

Kornitzer Capital Management’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-512,440	Closed	-$2.79M	–	475
2024 Q4	$2.79M	Sell	512,440 -7,450	-1%	-$47.9K	0.05%	287
2024 Q3	$4.32M	Buy	519,890 +3,725	+0.7%	+$32.2K	0.08%	251
2024 Q2	$3.7M	Hold	516,165	–	–	0.07%	269
2024 Q1	$4.48M	Hold	516,165	–	–	0.08%	262
2023 Q4	$3.38M	Hold	516,165	–	–	0.07%	278
2023 Q3	$5.16M	Hold	516,165	–	–	0.11%	246
2023 Q2	$6.42M	Buy	+516,165	New	+$6.97M	0.13%	232

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return

1WCM

12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

MFS

Mirabella Financial Services London, United Kingdom $1.06B AUM 19.83% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Kornitzer Capital Management's MRVI Position: Q1 2025 in Review

Kornitzer Capital Management sold out of Maravai LifeSciences (MRVI) in Q1 2025, closing a stake of 512,440 shares — an estimated $2.79M sold.

Kornitzer Capital Management first reported a position in MRVI in Q2 2023 and held it in 7 quarters. The position peaked at $6.42M in Q2 2023. 184 funds tracked by Wall St. Rank hold MRVI as of Q1 2025.

Kornitzer Capital Management reported no remaining Maravai LifeSciences position as of Q1 2025 after selling out during the quarter.
Kornitzer Capital Management sold 512,440 Maravai LifeSciences shares in Q1 2025, an estimated $2.79M.
Kornitzer Capital Management first reported a position in Maravai LifeSciences in Q2 2023 and held it in 7 quarters.
Kornitzer Capital Management's Maravai LifeSciences position peaked at $6.42M in Q2 2023.
184 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q1 2025.

Based on Kornitzer Capital Management's 13F filing for Q1 2025, filed 2 May 2025.